Nektar Therapeutics
NKTRNASDAQHealthcare● Active
$56.03
$-1.29(-2.25%)
Market Cap$1.1B
P/E Ratio—
52W High$109
52W Low$7.99
Nektar Therapeutics (NKTR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NKTR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.82
Est. -$1.74 · -4.6%
Revenue
$0.01B
Est. $0.01B · +1.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
NKTR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$2.05 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.74 | -$1.82 | -4.6% | $0.01B | $0.01B | +1.6% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$2.76 | -$1.78 | +35.5% | $0.02B | $0.01B | +114.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$2.85 | -$1.85 | +35.1% | $0.01B | $0.01B | +12.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$3.13 | -$2.95 | +5.8% | $0.01B | $0.01B | +18.7% |
| ▼ Q2 FY2025 | May 8, 2025 | -$2.70 | -$3.30 | -22.2% | $0.01B | $0.02B | -31.9% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -$1.95 | -$2.25 | -15.4% | $0.03B | $0.04B | -20.4% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.23 | -$0.18 | +21.7% | $0.02B | $0.03B | -23.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$2.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.82
EPS Est.
-$1.74
EPS Surpr.
-4.6%
Revenue
$0.01B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$1.78
EPS Est.
-$2.76
EPS Surpr.
+35.5%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$1.85
EPS Est.
-$2.85
EPS Surpr.
+35.1%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$2.95
EPS Est.
-$3.13
EPS Surpr.
+5.8%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$3.30
EPS Est.
-$2.70
EPS Surpr.
-22.2%
Revenue
$0.01B
Q1 FY2025
Mar 12, 2025Miss
EPS Actual
-$2.25
EPS Est.
-$1.95
EPS Surpr.
-15.4%
Revenue
$0.03B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.23
EPS Surpr.
+21.7%
Revenue
$0.02B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-3.85 | $-3.38 | $-2.02 | 4 |
| Q3 FY2029 | $-3.83 | $-3.36 | $-2.00 | 3 |
| Q2 FY2029 | $-4.11 | $-3.61 | $-2.15 | 3 |
| Q1 FY2029 | $-4.03 | $-3.54 | $-2.11 | 4 |
| Q4 FY2028 | $-3.79 | $-3.32 | $-1.98 | 3 |
| Q3 FY2028 | $-3.89 | $-3.41 | $-2.04 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -4.6% | $85.09 | $83.37 | -2.02% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +35.5% | $73.33 | $70.36 | -4.05% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +35.1% | $54.26 | $55.12 | +1.58% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +5.8% | $22.45 | $21.75 | -3.12% |
| ▼ Q2 FY2025 | May 8, 2025 | -22.2% | $9.08 | $9.28 | +2.20% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -15.4% | $12.29 | $12.30 | +0.08% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +21.7% | $20.85 | $20.55 | -1.44% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -19.1% | $17.70 | $18.15 | +2.54% |
Q2 FY2026-2.02%
Report Date
May 7, 2026
EPS Beat/Miss
-4.6%
Price Before
$85.09
Price After
$83.37
Q1 FY2026-4.05%
Report Date
Mar 12, 2026
EPS Beat/Miss
+35.5%
Price Before
$73.33
Price After
$70.36
Q4 FY2025+1.58%
Report Date
Nov 6, 2025
EPS Beat/Miss
+35.1%
Price Before
$54.26
Price After
$55.12
Q3 FY2025-3.12%
Report Date
Aug 7, 2025
EPS Beat/Miss
+5.8%
Price Before
$22.45
Price After
$21.75
Q2 FY2025+2.20%
Report Date
May 8, 2025
EPS Beat/Miss
-22.2%
Price Before
$9.08
Price After
$9.28
Q1 FY2025+0.08%
Report Date
Mar 12, 2025
EPS Beat/Miss
-15.4%
Price Before
$12.29
Price After
$12.30
Q4 FY2024-1.44%
Report Date
Nov 7, 2024
EPS Beat/Miss
+21.7%
Price Before
$20.85
Price After
$20.55
Q3 FY2024+2.54%
Report Date
Aug 8, 2024
EPS Beat/Miss
-19.1%
Price Before
$17.70
Price After
$18.15
Avg Beat Reaction-1.76%
Avg Miss Reaction+0.70%
Beat Rate4 / 8 quarters
Largest Move-4.05% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NKTR ends December
Nektar Therapeutics (NKTR) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.82 — missing the analyst consensus of $-1.74 by -4.6%. The next NKTR earnings date is expected around September 1, 2026.
Each quarter, investors track NKTR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NKTR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NKTR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NKTR earnings · 5 questionsNektar Therapeutics's next earnings report is expected around September 1, 2026. NKTR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NKTR historically reports after market close (AMC).
NKTR earnings datewhen is NKTR earningsNKTR next earnings datewhen does NKTR report earningsNKTR earnings calendar
▸ Source: FMP · Nektar Therapeutics SEC filings · US GAAP · Nektar Therapeutics SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026